A Review on Emerging Trends in the Diagnosis and Treatment of Anxiety Disorders
Rajkumar Chaudhary, Nilesh Chauhan*, Saloni Mishra, Abhishek Pratap, Dr. Rahul P. K. Mishra
Zenodo (CERN European Organization for Nuclear Research) April 4, 2026 DOI: 10.5281/zenodo.19415042 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Anxiety |
| Keywords | Neuromodulation Transcranial direct-current stimulation Mental health Neuroimaging Bench to bedside Wearable computer Precision medicine Brain stimulation Data science Personalized medicine Big data Transcranial magnetic stimulation Mhealth Wearable technology Sophistication Clinical psychology Digital health Interpretability Artificial intelligence |
| Key findings | Advances in digital phenotyping, AI, neuroimaging, psychedelic-assisted psychotherapy, neuromodulation, digital therapeutics, and precision pharmacology are transforming anxiety disorder diagnosis and treatment toward objective, predictive, personalized care, while raising challenges in privacy, access, and regulation. |
Abstract
Anxiety disorders represent the most prevalent class of mental health conditions globally, contributing significantly to disability and economic burden. While traditional diagnostic methods relying on clinician-administered scales and cognitive-behavioral therapies (CBT) remain foundational, a paradigm shift is underway. This review synthesizes the emerging trends revolutionizing the field, driven by advancements in technology and neuroscience. In diagnosis, we explore the move towards digital phenotyping through smartphone sensors and wearables for passive, continuous data collection, the application of artificial intelligence (AI) and machine learning (ML) for predictive analytics and personalized risk assessment, and the utilization of neuroimaging and biomarker research to establish objective biological correlates. In treatment, we examine the resurgence of psychedelic-assisted psychotherapy, the refinement of neuromodulation techniques like Transcranial Magnetic Stimulation (TMS) and transcranial Direct Current Stimulation (tDCS), the proliferation and increasing sophistication of digital therapeutics (DTx) and mobile health (mHealth) applications, and the promise of precision pharmacology guided by genetic profiling. This convergence of technology and biology is paving the way for a new era of objective, predictive, and highly personalized mental healthcare for anxiety disorders. However, these advancements are accompanied by significant challenges, including issues of data privacy, equitable access, and the need for robust regulatory frameworks, which are also discussed.